Research
Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
Nature ·
The Brief
- A study reports that targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression in HPV-negative head and neck squamous cell carcinoma (HNSCC).
- The study reports that this approach improves response to anti-PD-L1 therapy in HPV-negative HNSCC.
Why it matters
It suggests that targeting fibroblasts, rather than tumour cells alone, could make anti-PD-L1 immunotherapy more effective in HPV-negative head and neck cancer.
Who’s affected
- cancer researchers
- clinicians treating head and neck cancer
- #smyd3
- #hnscc
- #immunotherapy
- #pd-l1
- #cancer-associated-fibroblasts